WuXi AppTec Co Ltd
SSE:603259

Watchlist Manager
WuXi AppTec Co Ltd Logo
WuXi AppTec Co Ltd
SSE:603259
Watchlist
Price: 55.64 CNY -1.43% Market Closed
Market Cap: 160.7B CNY
Have any thoughts about
WuXi AppTec Co Ltd?
Write Note

WuXi AppTec Co Ltd
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

WuXi AppTec Co Ltd
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
WuXi AppTec Co Ltd
SSE:603259
Other Current Liabilities
¥6.4B
CAGR 3-Years
3%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Other Current Liabilities
¥1.7B
CAGR 3-Years
8%
CAGR 5-Years
31%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Other Current Liabilities
¥4.5B
CAGR 3-Years
12%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Other Current Liabilities
¥1.4B
CAGR 3-Years
20%
CAGR 5-Years
23%
CAGR 10-Years
35%
Genscript Biotech Corp
HKEX:1548
Other Current Liabilities
$223.1m
CAGR 3-Years
-3%
CAGR 5-Years
19%
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Other Current Liabilities
¥582.8m
CAGR 3-Years
211%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

WuXi AppTec Co Ltd
Glance View

Market Cap
162B CNY
Industry
Life Sciences Tools & Services

In the bustling corridors of global pharmaceuticals, WuXi AppTec Co Ltd. emerges as a vital bridge between expansive scientific potential and the practical demands of drug development. Founded in China, WuXi AppTec began its journey by transforming itself into a leading provider of R&D and manufacturing services to the pharmaceutical, biotech, and healthcare industries. With a broad portfolio that spans from the initial stages of drug discovery to the intricate processes of commercial production, WuXi AppTec offers an integrated platform to its clients. This platform allows global pharmaceutical companies, fledgling biotech firms, and even academic institutions to streamline their research initiatives, reduce development timelines, and ultimately bring therapeutic innovations to the market more efficiently. The company's business model thrives on its "one-stop-shop" approach, which is comprised of client-tailored solutions that address every stage of the drug development lifecycle. WuXi generates revenue through a variety of services, including laboratory testing, clinical trial support, and large-scale manufacturing. By leveraging its comprehensive capabilities in chemistry, biologics, and genomics, it successfully caters to a diversified clientele, ensuring sustainability through a steady stream of contract-based income. With an emphasis on advanced technologies and a global footprint that covers North America, Europe, and Asia, WuXi AppTec stands as a crucial ally to innovators ardently seeking to overcome the challenges of modern medicine by expediting the path from ‘concept’ to ‘cure’.

Intrinsic Value
88.23 CNY
Undervaluation 37%
Intrinsic Value
Price

See Also

What is WuXi AppTec Co Ltd's Other Current Liabilities?
Other Current Liabilities
6.4B CNY

Based on the financial report for Sep 30, 2024, WuXi AppTec Co Ltd's Other Current Liabilities amounts to 6.4B CNY.

What is WuXi AppTec Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
16%

Over the last year, the Other Current Liabilities growth was -21%. The average annual Other Current Liabilities growth rates for WuXi AppTec Co Ltd have been 3% over the past three years , 16% over the past five years .

Back to Top